RT Journal Article
SR Electronic
T1 695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON)
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A787
OP A787
DO 10.1136/jitc-2023-SITC2023.0695
VO 11
IS Suppl 1
A1 Cheema, Parneet
A1 Hartl, Sylvia
A1 Koczywas, Marianna
A1 Hochmair, Maximilian
A1 Shepherd, Frances A
A1 Chu, Quincy
A1 Galletti, Giuseppe
A1 Gustavson, Mark
A1 Iyer, Sonia
A1 Carl Barrett, J
A1 Evans, Brent
A1 Kumar, Rakesh
A1 Cosaert, Jan
A1 Park, Keunchil
A1 Heymach, John V
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A787.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.